ACO: Time to move from the description of different phenotypes to the treatable traits.
BACKGROUND:Asthma-COPD overlap (ACO) is a term that encompasses patients with characteristics of two conditions, smoking asthmatics or COPD patients with asthma-like features such as high bronchodilator response or blood eosinophil count ≥300 cells/μL. The aim of this study was to compare the differ...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2019-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0210915 |
| _version_ | 1818589038104281088 |
|---|---|
| author | Nuria Toledo-Pons Job F M van Boven Miguel Román-Rodríguez Noemí Pérez Jose Luis Valera Felices Joan B Soriano Borja G Cosío |
| author_facet | Nuria Toledo-Pons Job F M van Boven Miguel Román-Rodríguez Noemí Pérez Jose Luis Valera Felices Joan B Soriano Borja G Cosío |
| author_sort | Nuria Toledo-Pons |
| collection | DOAJ |
| description | BACKGROUND:Asthma-COPD overlap (ACO) is a term that encompasses patients with characteristics of two conditions, smoking asthmatics or COPD patients with asthma-like features such as high bronchodilator response or blood eosinophil count ≥300 cells/μL. The aim of this study was to compare the different phenotypes inside the ACO definition in a real-life population cohort. METHODS:We analyzed patients from the MAJORICA cohort who had a diagnosis of asthma and/or COPD based on current guidelines, laboratory data in 2014 and follow-up until 2015. Prevalence of ACO according to the different criteria, demographic, clinical and functional characteristics, prescriptions and use of health resources data were compared between three groups. RESULTS:We included 603 patients. Prevalence of smoking asthmatics was 14%, COPD patients with high bronchodilator response 1.5% and eosinophilic COPD patients 12%. Smoking asthmatics were younger and used more rescue inhalers, corticosteroids and health resources. Conversely, eosinophilic COPD patients were older than the other groups, often treated with corticosteroids and had lower use of health resources. Most of the COPD patients with high bronchodilator response were included in the eosinophilic COPD group. CONCLUSIONS:ACO includes two conditions (smoking asthmatics and eosinophilic COPD patients) with different medication requirement and prognosis that should not be pooled together. Use of ≥300 blood eosinophils/μL as a treatable trait should be recommended. |
| first_indexed | 2024-12-16T09:34:17Z |
| format | Article |
| id | doaj.art-47077e6b699f4aa5b5bc39b8d212bf78 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-16T09:34:17Z |
| publishDate | 2019-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-47077e6b699f4aa5b5bc39b8d212bf782022-12-21T22:36:26ZengPublic Library of Science (PLoS)PLoS ONE1932-62032019-01-01141e021091510.1371/journal.pone.0210915ACO: Time to move from the description of different phenotypes to the treatable traits.Nuria Toledo-PonsJob F M van BovenMiguel Román-RodríguezNoemí PérezJose Luis Valera FelicesJoan B SorianoBorja G CosíoBACKGROUND:Asthma-COPD overlap (ACO) is a term that encompasses patients with characteristics of two conditions, smoking asthmatics or COPD patients with asthma-like features such as high bronchodilator response or blood eosinophil count ≥300 cells/μL. The aim of this study was to compare the different phenotypes inside the ACO definition in a real-life population cohort. METHODS:We analyzed patients from the MAJORICA cohort who had a diagnosis of asthma and/or COPD based on current guidelines, laboratory data in 2014 and follow-up until 2015. Prevalence of ACO according to the different criteria, demographic, clinical and functional characteristics, prescriptions and use of health resources data were compared between three groups. RESULTS:We included 603 patients. Prevalence of smoking asthmatics was 14%, COPD patients with high bronchodilator response 1.5% and eosinophilic COPD patients 12%. Smoking asthmatics were younger and used more rescue inhalers, corticosteroids and health resources. Conversely, eosinophilic COPD patients were older than the other groups, often treated with corticosteroids and had lower use of health resources. Most of the COPD patients with high bronchodilator response were included in the eosinophilic COPD group. CONCLUSIONS:ACO includes two conditions (smoking asthmatics and eosinophilic COPD patients) with different medication requirement and prognosis that should not be pooled together. Use of ≥300 blood eosinophils/μL as a treatable trait should be recommended.https://doi.org/10.1371/journal.pone.0210915 |
| spellingShingle | Nuria Toledo-Pons Job F M van Boven Miguel Román-Rodríguez Noemí Pérez Jose Luis Valera Felices Joan B Soriano Borja G Cosío ACO: Time to move from the description of different phenotypes to the treatable traits. PLoS ONE |
| title | ACO: Time to move from the description of different phenotypes to the treatable traits. |
| title_full | ACO: Time to move from the description of different phenotypes to the treatable traits. |
| title_fullStr | ACO: Time to move from the description of different phenotypes to the treatable traits. |
| title_full_unstemmed | ACO: Time to move from the description of different phenotypes to the treatable traits. |
| title_short | ACO: Time to move from the description of different phenotypes to the treatable traits. |
| title_sort | aco time to move from the description of different phenotypes to the treatable traits |
| url | https://doi.org/10.1371/journal.pone.0210915 |
| work_keys_str_mv | AT nuriatoledopons acotimetomovefromthedescriptionofdifferentphenotypestothetreatabletraits AT jobfmvanboven acotimetomovefromthedescriptionofdifferentphenotypestothetreatabletraits AT miguelromanrodriguez acotimetomovefromthedescriptionofdifferentphenotypestothetreatabletraits AT noemiperez acotimetomovefromthedescriptionofdifferentphenotypestothetreatabletraits AT joseluisvalerafelices acotimetomovefromthedescriptionofdifferentphenotypestothetreatabletraits AT joanbsoriano acotimetomovefromthedescriptionofdifferentphenotypestothetreatabletraits AT borjagcosio acotimetomovefromthedescriptionofdifferentphenotypestothetreatabletraits |